Abstract
Although a majority of high-grade gliomas express the apoptosis-inducing receptor Fas, little is known about the extent of apoptosis or prognostic significance of Fas expression in these tumors. In situ labeling of apoptotic cells and Ki-67 immunohistochemistry were performed on 51 high-grade human astrocytomas previously characterized for Fas expression. Survival data was compiled from patient records and correlated with tumor grade, apoptotic index (AI) and Fas expression. A significant correlation was found between tumor grade and the AI and Ki-67 labeling index (LI); however, only the AI increased significantly with Fas expression. The AI increased from 0.39 ± 0.12% to 0.82 ± 0.10% in grade III vs. IV astrocytomas (P = 0.003). The Ki-67-LI increased from 3.64 ± 1.5% to 11.35 ± 2.1% in grade III vs. IV astrocytomas (P = 0.004). Additionally, tumors expressing higher Fas levels had a greater AI than those expressing lower levels (0.81 ± 0.11% vs. 0.43 ± 0.11%) (P = 0.017). Despite longer median survivals for patients with tumors exhibiting high Fas expression, statistical significance was not achieved. Patients with grade III astrocytomas demonstrated a median survival of 20 vs. 18 months for tumors with high vs. low Fas expression (P = 0.51). Patients with grade IV astrocytomas demonstrated a median survival of 9 vs. 7.4 months for tumors with high vs. low Fas expression, respectively (P = 0.77). Although the degree of Fas expression in high-grade astrocytomas appears to correlate with the apoptotic rate, no overall differences in survival could be demonstrated between tumors expressing high vs. low Fas levels.
Similar content being viewed by others
References
Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440–1443, 1985
Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumors and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352–361, 1995
Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013–2026, 1994
Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146: 3–15, 1995
Imitola J, Nikas DC, Black PM: Apoptosis in tumors of the central nervous system. Crit Rev Neurosurg 7: 391–399, 1997
Kordek R, Hironishi M, Liberski PP, Yanagihara R, Gajdusek DC: Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol (Berl) 91: 112–116, 1996
Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima SI, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233–243, 1991
Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178, 1993
Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78–81, 1995
Walker PR, Saas P, Dietrich PY: Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back. J Immunol 158: 4521–4524, 1997
Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H: Expression of Fas/ APO-1 during the progression of astrocytomas. Cancer Res 55: 5528–5530, 1995
Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431–434, 1996
Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT: Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol 95: 287–290, 1998
Frankel B, Longo SL, Ryken TC: Human astrocytomas co-expressing Fas and Fas ligand also produce TGFβ2 and Bcl-2. J Neuro-Oncol 44: 205–212, 1999
Frankel B, Longo SL, Ryken TC: Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors. Acta Neuropathol (Berl) 98: 363–366, 1999
Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415–429, 1993
Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-fas/APO1 antibody-mediated apoptosis of cultured human glioma cells: Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954–964, 1994
Weller M, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: Lethal weapon against malignant glioma? Brain Pathol 8: 285–293, 1998
Frei K, Ambar B, Adachi N, Yonekawa Y, Fontana A: Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. J Neuroimmunol 87: 105–113, 1998
Toda K, Shiraishi T, Hirotsu T, Fukuyama K, Mineta T, Kawaguchi S, Tabuchi K: The cytocidal activity of OK-432–activated mononuclear cells against human glioma cells is partly mediated through the Fas ligand/Fas system. Jpn J Cancer Res 87: 972–976, 1996
Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H: Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863–869, 1997
Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET: Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56: 857–865, 1997
Schiffer D, Cavalla P, Migheli A, Chiò A, Giordana MT, Marino S, Attanasio A: Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 195: 81–84, 1995
Migheli A, Cavalla P, Marino S, Schiffer D: A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 53: 606–616, 1994
Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas/Apo-1 gene transfer for human malignant glioma. Cancer Res 55: 2936–2944, 1995
Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633–2643, 1995
Kawahara A, Kobayashi T, Nagata S: Inhibition of Fas-induced apoptosis by Bcl-2. Oncogene 17: 2549–2554, 1998
Yeh JH, Hsu SC, Han SH, Lai MZ: Mitogen-activated protein kinase antagonized Fas-associated death domain 34 protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J Exp Med 188: 1795–1802, 1998
O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The fas counterattack: cancer as a site of immune privilege. Immunol Today 20: 46–52, 1999
Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, Lassmann H: Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 71: 219–225, 1994
Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H: The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? Hepatol 30: 413–421, 1999
Koomägi R, Volm M: Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239–243, 1999
Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T: Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer 80: 2133–2140, 1997
Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol (Berl) 87: 47–54, 1994
Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value. J Neuro-Oncol 44: 255–266, 1999
Frankel B, Longo SL, Kyle M, Canute GW, Ryken TC: Fas upregulation in high-grade gliomas results in increased apoptosis and survival. Neurosurg 49: 2001
Kamada H, Murakami H, Satone A, Ikeda M, Yamaguchi H, Matsumoto A, IdeW, Hashimoto I, Ukita H: [Up-regulation of NGF, trkA, Fas, down-regulation of bcl-2, and induction of apoptosis by propentofylline in human glioma cell lines]. No To Shinkei 48: 1022–1028, 1996
Jiang S, Song MJ, Shin EC, Lee MO, Kim SJ, Park JH: Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatol 29: 101–110, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frankel, B., Longo, S.L., Leach, C. et al. Apoptosis and Survival in High-grade Astrocytomas as Related to Tumor Fas (APO-1/CD95) Expression. J Neurooncol 59, 27–34 (2002). https://doi.org/10.1023/A:1016329231461
Issue Date:
DOI: https://doi.org/10.1023/A:1016329231461